Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
Sentynl Therapeutics secures $40 million deal with Mereo Biopharma for exclusive marketing rights of alvelestat in the U.S. The agreement includes upfront and R&D payments.
PRIVATEAug 14, 2026•about 17 hours ago
Amount Raised
$40 Million
Round Type
Venture - Series Unknown
Solana BeachBiotechnologyTherapeuticsPharmaceuticalDescription
Sentynl Therapeutics has paid an undisclosed fee for the exclusive option to market Mereo Biopharma’s drug alvelestat in the U.S. If Sentynl exercises that option, it will pay $40 million to Mereo. This payment covers the deal’s upfront and R&D expenses until the submission of a new drug application. This strategic move highlights Sentynl's growth plans and commitment to advancing valuable treatments.
Don't miss Sentynl Therapeutics's next move
Get an email the moment Sentynl Therapeutics raises, hires an exec, or expands — usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
Suggested for you
1 contactFunding Insights
Based on industry dataTech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech